Sutro Biopharma (STRO) Return on Capital Employed (2018 - 2025)
Sutro Biopharma's (STRO) quarterly Return on Capital Employed came in at 135.81% in Q4 2025, down 5290.0% year-on-year from 2.62% in Q4 2024, and down 20.1% quarter-over-quarter from 113.08% in Q3 2025.
Sutro Biopharma (STRO) Return on Capital Employed (2018 - 2025) Analysis & Trends
Sutro Biopharma has disclosed Return on Capital Employed across 8 years of filings, most recently posting 135.81% for Q4 2025.
- Return on Capital Employed for Q4 2025 came in at 135.81%, down 5290.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 135.81% (down 5290.0% YoY), and the FY2025 annual result was 77.11%, up 316.0% from the prior year.
- Return on Capital Employed came in at 135.81% for Q4 2025 at Sutro Biopharma, down from 113.08% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 19.3% in Q2 2021 to a low of 135.81% in Q4 2025.
- The 5-year median for Return on Capital Employed is 39.61% (2023), against an average of 52.75%.
- Across the five-year window, Return on Capital Employed soared 2900 bps in 2021 and slumped 8417 bps in 2025, its largest moves.
- Sutro Biopharma's Return on Capital Employed stood at 31.31% in 2021, then declined by 22 bps to 38.23% in 2022, then jumped by 35 bps to 24.97% in 2023, then sank by 232 bps to 82.9% in 2024, then slumped by 64 bps to 135.81% in 2025.
- The last three Return on Capital Employed figures came in at 135.81% (Q4 2025), 113.08% (Q3 2025), and 94.21% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Sutro Biopharma | 252.04 Mn | 252.04 Mn | - | -135.81% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -135.81% |
| Sep 30, 2025 | -113.08% |
| Jun 30, 2025 | -94.21% |
| Mar 31, 2025 | -113.15% |
| Dec 31, 2024 | -82.90% |
| Sep 30, 2024 | -38.34% |
| Jun 30, 2024 | -33.56% |
| Mar 31, 2024 | -28.98% |
| Dec 31, 2023 | -24.97% |
| Sep 30, 2023 | -48.48% |
| Jun 30, 2023 | -46.13% |
| Mar 31, 2023 | -40.88% |
| Dec 31, 2022 | -38.23% |
| Sep 30, 2022 | -34.27% |
| Jun 30, 2022 | -42.73% |
| Mar 31, 2022 | -41.81% |
| Dec 31, 2021 | -31.31% |
| Sep 30, 2021 | -26.75% |
| Jun 30, 2021 | -19.30% |
| Mar 31, 2021 | -20.04% |